Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionPhraction Management LLC
Latest Disclosed Ownership367 shares
Latest Disclosed Value $ 283,559
Phraction Management LLC ownership in REGN / Regeneron Pharmaceuticals, Inc.

On April 23, 2026 - Phraction Management LLC filed a 13F-HR form disclosing ownership of 367 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $283,559 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 26, 2026 disclosing 367 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-23 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 284 0.00 0.0587
2026-01-26 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 283 37.38 0.0755
2025-10-09 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 367 367 206 0.0596
2025-07-21 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -367 -100.00 0 -100.00
2025-04-28 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 233 -11.11 0.0780
2025-01-29 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 261 -32.21 0.0917
2024-11-06 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 386 0.00 0.1364
2024-08-01 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 386 9.07 0.1410
2024-05-13 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 353 9.63 0.1359
2024-02-05 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 322 6.62 0.1332
2023-11-08 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 367 0 0.00 302 14.83 0.1424
2023-08-03 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 367 -95 -20.56 264 -30.61 0.1302
2023-04-28 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 462 -90 -16.30 380 -4.77 0.2177
2023-02-07 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 552 0 0.00 398 4.74 0.2614
2022-11-02 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 552 50 9.96 380 27.95 0.2870
2022-08-08 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 502 502 297 0.1952
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.